---
layout: post
title: "八大券商主题策略：新冠药物、检测、消费医疗、中药 医疗又一细分领域要崛起了？"
date: 2022-05-12 12:07:05 +0800
categories: emnews
tags: 东财滚动新闻
---
> 德邦证券表示，随着天气回暖，我们判断国内本轮疫情防控有望迎来末尾阶段，国内经济和消费复苏在即。配置和估值方面：虽然22Q1医药获得主动偏股基金逆市加仓，与历史相比，仍属低配区间。年报和一季报的总结：医药整体业绩仍然不错，CXO、IVD、制药上游和疫苗等表现亮眼，很多板块估值已处于历史底部区间，配置性价比很高。

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1060" data-code="BK1060|90|1" data-code2="BK1060|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1060&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1060_0" data-code="K BK1060|90|1" data-code2="K BK1060|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1062" data-code="BK1062|90|1" data-code2="BK1062|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1062&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1062_0" data-code="K BK1062|90|1" data-code2="K BK1062|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" data-code="BK1041|90|1" data-code2="BK1041|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1041&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1041_0" data-code="K BK1041|90|1" data-code2="K BK1041|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" data-code="BK1040|90|1" data-code2="BK1040|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1040&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1040_0" data-code="K BK1040|90|1" data-code2="K BK1040|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>每日主题策略讨论，<span id="stock_0.300059"><a href="http://quote.eastmoney.com/unify/r/0.300059" class="keytip" data-code="0,300059">东方财富</a></span><span id="quote_0.300059"></span>网汇总八大<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>观点，揭秘行业现状，观察行情走势，提前为您把脉A股。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D25727522815913027860_w558h461.jpg" width="558" emheight="461" orginial_src="https://dfscdn.dfcfw.com/download/D25727522815913027860_w558h461_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>德邦<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>：“新冠口服药物+消费医疗”仍为重点</strong></p><p>随着天气回暖，我们判断国内本轮疫情防控有望迎来末尾阶段，国内经济和消费复苏在即。配置和估值方面：虽然22Q1医药获得主动偏<span id="Info.3123"><a href="http://fund.eastmoney.com/GP_jzzzl.html" class="infokey">股基</a></span>金逆市加仓，与历史相比，仍属低配区间。年报和一季报的总结：医药整体<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>仍然不错，CXO、IVD、制药上游和疫苗等表现亮眼，很多板块估值已处于历史底部区间，配置性价比很高。</p><p>我们建议重点方向具体如下：一、疫情防控条线：当前亟需补充新冠口服药物，建议关注：1、<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>新冠小分子产业链：1)MPP授权企业：<span id="stock_1.600521"><a href="http://quote.eastmoney.com/unify/r/1.600521" class="keytip" data-code="1,600521">华海药业</a></span><span id="quote_1.600521"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>和<span id="stock_0.000739"><a href="http://quote.eastmoney.com/unify/r/0.000739" class="keytip" data-code="0,000739">普洛药业</a></span><span id="quote_0.000739"></span>等；2)CDMO:<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>、<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>等；3)中间体：<span id="stock_0.300233"><a href="http://quote.eastmoney.com/unify/r/0.300233" class="keytip" data-code="0,300233">金城医药</a></span><span id="quote_0.300233"></span>、<span id="stock_1.603520"><a href="http://quote.eastmoney.com/unify/r/1.603520" class="keytip" data-code="1,603520">司太立</a></span><span id="quote_1.603520"></span>等；2、国产新冠口服小分子，重点：<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>研发的VV116，已启动全球多中心三期和国内<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>药物头对头试验已经完成入组；</p><p>二、复产预期下，消费医疗值得关注：本轮疫情解封后，医疗消费需求将快速复苏，建议关注：<span id="stock_0.300015"><a href="http://quote.eastmoney.com/unify/r/0.300015" class="keytip" data-code="0,300015">爱尔眼科</a></span><span id="quote_0.300015"></span>、<span id="stock_1.600763"><a href="http://quote.eastmoney.com/unify/r/1.600763" class="keytip" data-code="1,600763">通策医疗</a></span><span id="quote_1.600763"></span>、<span id="stock_0.301103"><a href="http://quote.eastmoney.com/unify/r/0.301103" class="keytip" data-code="0,301103">何氏眼科</a></span><span id="quote_0.301103"></span>等。</p><p>三、持续看好<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>板块：<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>板块短期回调显著，基本面和政策面没有变化，部分板块和公司业绩确定性强，重点关注：<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>、<span id="stock_1.603858"><a href="http://quote.eastmoney.com/unify/r/1.603858" class="keytip" data-code="1,603858">步长制药</a></span><span id="quote_1.603858"></span>、<span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span>、<span id="Info.116.00570"><a href="http://quote.eastmoney.com/unify/r/116.00570" class="keytip" data-code="116,00570">中国中药</a></span>、<span id="stock_1.600085"><a href="http://quote.eastmoney.com/unify/r/1.600085" class="keytip" data-code="1,600085">同仁堂</a></span><span id="quote_1.600085"></span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>、<span id="stock_1.600422"><a href="http://quote.eastmoney.com/unify/r/1.600422" class="keytip" data-code="1,600422">昆药集团</a></span><span id="quote_1.600422"></span>和<span id="stock_1.600976"><a href="http://quote.eastmoney.com/unify/r/1.600976" class="keytip" data-code="1,600976">健民集团</a></span><span id="quote_1.600976"></span>等。</p><p>四、坚持业绩为王，关注低估值、高增长的公司：如<span id="stock_0.000661"><a href="http://quote.eastmoney.com/unify/r/0.000661" class="keytip" data-code="0,000661">长春高新</a></span><span id="quote_0.000661"></span>、<span id="stock_0.301096"><a href="http://quote.eastmoney.com/unify/r/0.301096" class="keytip" data-code="0,301096">百诚医药</a></span><span id="quote_0.301096"></span>、<span id="stock_0.300705"><a href="http://quote.eastmoney.com/unify/r/0.300705" class="keytip" data-code="0,300705">九典制药</a></span><span id="quote_0.300705"></span>和<span id="stock_0.300573"><a href="http://quote.eastmoney.com/unify/r/0.300573" class="keytip" data-code="0,300573">兴齐眼药</a></span><span id="quote_0.300573"></span>等。</p><p><strong>上海<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：常态化核酸+抗原检测全面铺开 看好检测和复苏两大逻辑</strong></p><p>常态化核酸+抗原检测将带来更强的复苏预期，看好消费医疗、<span id="bk_90.BK0727"><a href="http://quote.eastmoney.com/unify/r/90.BK0727" class="keytip" data-code="90,BK0727">医疗服务</a></span><span id="bkquote_90.BK0727"></span>和零售、院内诊疗的恢复。常态化核酸+抗原检测符合我国疫情防控政策总方针，可以在病毒传播初期精准切断传播链，尽可能减少后续大面积封城带来的经济成本，有助于加快恢复社会的正常运转。</p><p>围绕检测和复苏两大主线，我们认为前期受损较为明显的消费医疗、<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0727" class="em_stock_key_common" data-code="90,BK0727">医疗服务</span>和零售、院内诊疗等板块有望逐步修复。同时可以重点关注检测板块中兼具核酸+抗原产品、拥有成本优势的龙头公司。</p><p>投资建议来看，检测板块建议关注<span id="stock_0.002932"><a href="http://quote.eastmoney.com/unify/r/0.002932" class="keytip" data-code="0,002932">明德生物</a></span><span id="quote_0.002932"></span>、<span id="stock_1.688289"><a href="http://quote.eastmoney.com/unify/r/1.688289" class="keytip" data-code="1,688289">圣湘生物</a></span><span id="quote_1.688289"></span>等；核酸检测上游建议关注<span id="stock_1.688139"><a href="http://quote.eastmoney.com/unify/r/1.688139" class="keytip" data-code="1,688139">海尔生物</a></span><span id="quote_1.688139"></span>、<span id="stock_1.603987"><a href="http://quote.eastmoney.com/unify/r/1.603987" class="keytip" data-code="1,603987">康德莱</a></span><span id="quote_1.603987"></span>、<span id="stock_1.605369"><a href="http://quote.eastmoney.com/unify/r/1.605369" class="keytip" data-code="1,605369">拱东医疗</a></span><span id="quote_1.605369"></span>、<span id="stock_0.300887"><a href="http://quote.eastmoney.com/unify/r/0.300887" class="keytip" data-code="0,300887">谱尼测试</a></span><span id="quote_0.300887"></span>；消费医疗及<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0727" class="em_stock_key_common" data-code="90,BK0727">医疗服务</span>板块建议关注龙头<span web="1" href="http://quote.eastmoney.com/unify/r/0.300015" class="em_stock_key_common" data-code="0,300015">爱尔眼科</span>、<span id="stock_0.300595"><a href="http://quote.eastmoney.com/unify/r/0.300595" class="keytip" data-code="0,300595">欧普康视</a></span><span id="quote_0.300595"></span>、<span id="stock_0.301087"><a href="http://quote.eastmoney.com/unify/r/0.301087" class="keytip" data-code="0,301087">可孚医疗</a></span><span id="quote_0.301087"></span>等；医疗零售板块建议关注<span id="stock_1.603939"><a href="http://quote.eastmoney.com/unify/r/1.603939" class="keytip" data-code="1,603939">益丰药房</a></span><span id="quote_1.603939"></span>、<span id="stock_1.603233"><a href="http://quote.eastmoney.com/unify/r/1.603233" class="keytip" data-code="1,603233">大参林</a></span><span id="quote_1.603233"></span>、<span id="stock_1.603883"><a href="http://quote.eastmoney.com/unify/r/1.603883" class="keytip" data-code="1,603883">老百姓</a></span><span id="quote_1.603883"></span>、<span id="stock_0.002727"><a href="http://quote.eastmoney.com/unify/r/0.002727" class="keytip" data-code="0,002727">一心堂</a></span><span id="quote_0.002727"></span>、<span id="stock_1.605266"><a href="http://quote.eastmoney.com/unify/r/1.605266" class="keytip" data-code="1,605266">健之佳</a></span><span id="quote_1.605266"></span>等。</p><p><strong><span id="stock_1.601881"><a href="http://quote.eastmoney.com/unify/r/1.601881" class="keytip" data-code="1,601881">中国银河</a></span><span id="quote_1.601881"></span><span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：景气度仍追逐疫情热点 困境反转仍需时日</strong></p><p>当前医药板块业绩仍主要受疫情节奏驱动。对于疫苗，要关注新冠病毒变异至何种版本才能达到稳定状态，以及针对变异的新冠病毒研发的新版疫苗接种需求。对于体外检测以及自检试剂盒等新冠检测概念，要关注新冠疫情波动周期是否越来越频繁，国内检测产品降价幅度，以及外国筛查力度是否大幅减弱。当前时点所得信息仍不足以将疫情因素视为短期因素，应当以中长期视角判断“困境反转”领域的基本面。</p><p>医药板块中最主要的疫情受损领域是除新冠之外的传染病用药以及除新冠疫苗之外的其他疫苗需求。目前新冠病毒变异传染性增加，重症率和死亡率仍然没有低到可以放开的程度。新冠疫情早已不是短期影响因素，应至少被视为中期影响因素。因此，等待疫情受损领域困境反转仍需时日，必须保持耐心。</p><p><strong><span id="stock_1.600909"><a href="http://quote.eastmoney.com/unify/r/1.600909" class="keytip" data-code="1,600909">华安证券</a></span><span id="quote_1.600909"></span>：“疫情”主线往复 “药+检测”重视程度提升</strong></p><p>业绩季节落幕，“疫情”主线往复，“药+检测”重视程度提升。估值角度看，医药不应该再悲观，医药已经是历史估值中枢下游合理区间，具备极强的投资配置价值。我们建议今年全年的方向配置：<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>(政策友好+低估值)+医疗设备(医疗基建)+科研试剂和上游等(自主可控)+其他方向自下而上寻找标的。</p><p>具体投资思路如下：(1)中药板块(品牌名贵OTC+中药创新药)：<span web="1" href="http://quote.eastmoney.com/unify/r/1.600085" class="em_stock_key_common" data-code="1,600085">同仁堂</span>、<span id="stock_1.600771"><a href="http://quote.eastmoney.com/unify/r/1.600771" class="keytip" data-code="1,600771">广誉远</a></span><span id="quote_1.600771"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000999" class="em_stock_key_common" data-code="0,000999">华润三九</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>、<span id="stock_1.600557"><a href="http://quote.eastmoney.com/unify/r/1.600557" class="keytip" data-code="1,600557">康缘药业</a></span><span id="quote_1.600557"></span>、<span id="stock_0.002873"><a href="http://quote.eastmoney.com/unify/r/0.002873" class="keytip" data-code="0,002873">新天药业</a></span><span id="quote_0.002873"></span>、<span id="stock_1.603439"><a href="http://quote.eastmoney.com/unify/r/1.603439" class="keytip" data-code="1,603439">贵州三力</a></span><span id="quote_1.603439"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600976" class="em_stock_key_common" data-code="1,600976">健民集团</span>、<span id="stock_1.600436"><a href="http://quote.eastmoney.com/unify/r/1.600436" class="keytip" data-code="1,600436">片仔癀</a></span><span id="quote_1.600436"></span>、<span id="stock_0.002728"><a href="http://quote.eastmoney.com/unify/r/0.002728" class="keytip" data-code="0,002728">特一药业</a></span><span id="quote_0.002728"></span>等标的，也推荐关注：<span id="stock_1.600535"><a href="http://quote.eastmoney.com/unify/r/1.600535" class="keytip" data-code="1,600535">天士力</a></span><span id="quote_1.600535"></span>、<span id="stock_1.603998"><a href="http://quote.eastmoney.com/unify/r/1.603998" class="keytip" data-code="1,603998">方盛制药</a></span><span id="quote_1.603998"></span>、<span id="stock_0.002275"><a href="http://quote.eastmoney.com/unify/r/0.002275" class="keytip" data-code="0,002275">桂林三金</a></span><span id="quote_0.002275"></span>、<span id="stock_1.603896"><a href="http://quote.eastmoney.com/unify/r/1.603896" class="keytip" data-code="1,603896">寿仙谷</a></span><span id="quote_1.603896"></span>等标的。</p><p>(2)中医疗服诊疗板块：<span id="Info.116.02273"><a href="http://quote.eastmoney.com/unify/r/116.02273" class="keytip" data-code="116,02273">固生堂</a></span>(中医疗服务龙头先锋)。</p><p>(3)医疗基建板块：我们持续推荐<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>(最受益医疗基建，也国际化)、<span id="stock_0.300453"><a href="http://quote.eastmoney.com/unify/r/0.300453" class="keytip" data-code="0,300453">三鑫医疗</a></span><span id="quote_0.300453"></span>，建议关注<span id="stock_1.688626"><a href="http://quote.eastmoney.com/unify/r/1.688626" class="keytip" data-code="1,688626">翔宇医疗</a></span><span id="quote_1.688626"></span>、<span id="stock_1.688580"><a href="http://quote.eastmoney.com/unify/r/1.688580" class="keytip" data-code="1,688580">伟思医疗</a></span><span id="quote_1.688580"></span>、<span id="stock_0.300633"><a href="http://quote.eastmoney.com/unify/r/0.300633" class="keytip" data-code="0,300633">开立医疗</a></span><span id="quote_0.300633"></span>、<span id="stock_1.688212"><a href="http://quote.eastmoney.com/unify/r/1.688212" class="keytip" data-code="1,688212">澳华内镜</a></span><span id="quote_1.688212"></span>、<span id="stock_0.300206"><a href="http://quote.eastmoney.com/unify/r/0.300206" class="keytip" data-code="0,300206">理邦仪器</a></span><span id="quote_0.300206"></span>、<span id="stock_0.002223"><a href="http://quote.eastmoney.com/unify/r/0.002223" class="keytip" data-code="0,002223">鱼跃医疗</a></span><span id="quote_0.002223"></span>等，此外，IVD 板块其实也会受益于医疗基建，推荐关注<span id="stock_0.300832"><a href="http://quote.eastmoney.com/unify/r/0.300832" class="keytip" data-code="0,300832">新产业</a></span><span id="quote_0.300832"></span>、<span id="stock_1.688575"><a href="http://quote.eastmoney.com/unify/r/1.688575" class="keytip" data-code="1,688575">亚辉龙</a></span><span id="quote_1.688575"></span>、<span id="stock_1.603658"><a href="http://quote.eastmoney.com/unify/r/1.603658" class="keytip" data-code="1,603658">安图生物</a></span><span id="quote_1.603658"></span>、<span id="stock_1.688389"><a href="http://quote.eastmoney.com/unify/r/1.688389" class="keytip" data-code="1,688389">普门科技</a></span><span id="quote_1.688389"></span>、<span id="stock_0.300463"><a href="http://quote.eastmoney.com/unify/r/0.300463" class="keytip" data-code="0,300463">迈克生物</a></span><span id="quote_0.300463"></span>、<span id="stock_0.300642"><a href="http://quote.eastmoney.com/unify/r/0.300642" class="keytip" data-code="0,300642">透景生命</a></span><span id="quote_0.300642"></span>、<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002932" class="em_stock_key_common" data-code="0,002932">明德生物</span>等，IVD 企业在疫情防控中起到重要作用(抗体、抗原与核酸检测试剂)，其为未来公司的发展提供了充足的资金。</p><p>(4)科研试剂和上游等：我们提议关注<span id="stock_1.688105"><a href="http://quote.eastmoney.com/unify/r/1.688105" class="keytip" data-code="1,688105">诺唯赞</a></span><span id="quote_1.688105"></span>、<span id="stock_1.688690"><a href="http://quote.eastmoney.com/unify/r/1.688690" class="keytip" data-code="1,688690">纳微科技</a></span><span id="quote_1.688690"></span>、<span id="stock_0.301080"><a href="http://quote.eastmoney.com/unify/r/0.301080" class="keytip" data-code="0,301080">百普赛斯</a></span><span id="quote_0.301080"></span>、<span id="stock_1.688133"><a href="http://quote.eastmoney.com/unify/r/1.688133" class="keytip" data-code="1,688133">泰坦科技</a></span><span id="quote_1.688133"></span>、<span id="stock_1.688179"><a href="http://quote.eastmoney.com/unify/r/1.688179" class="keytip" data-code="1,688179">阿拉丁</a></span><span id="quote_1.688179"></span>、<span id="stock_1.688026"><a href="http://quote.eastmoney.com/unify/r/1.688026" class="keytip" data-code="1,688026">洁特生物</a></span><span id="quote_1.688026"></span>、<span id="stock_0.300171"><a href="http://quote.eastmoney.com/unify/r/0.300171" class="keytip" data-code="0,300171">东富龙</a></span><span id="quote_0.300171"></span>、<span id="stock_0.300203"><a href="http://quote.eastmoney.com/unify/r/0.300203" class="keytip" data-code="0,300203">聚光科技</a></span><span id="quote_0.300203"></span>、<span id="stock_0.300358"><a href="http://quote.eastmoney.com/unify/r/0.300358" class="keytip" data-code="0,300358">楚天科技</a></span><span id="quote_0.300358"></span>、<span id="stock_0.300813"><a href="http://quote.eastmoney.com/unify/r/0.300813" class="keytip" data-code="0,300813">泰林生物</a></span><span id="quote_0.300813"></span>、<span id="stock_1.688265"><a href="http://quote.eastmoney.com/unify/r/1.688265" class="keytip" data-code="1,688265">南模生物</a></span><span id="quote_1.688265"></span>等。</p><p>(5)其他自下而上的板块和公司，需要根据行业和公司的标的和估值去做分析，提议关注：再生医学板块的<span id="stock_0.300653"><a href="http://quote.eastmoney.com/unify/r/0.300653" class="keytip" data-code="0,300653">正海生物</a></span><span id="quote_0.300653"></span>、<span id="stock_0.301033"><a href="http://quote.eastmoney.com/unify/r/0.301033" class="keytip" data-code="0,301033">迈普医学</a></span><span id="quote_0.301033"></span>等标的；医疗服务板块，我们推荐具备性价比和扩张性强的海吉亚、<span web="1" href="http://quote.eastmoney.com/unify/r/116.02273" class="em_stock_key_common" data-code="116,02273">固生堂</span>、<span id="Info.116.01951"><a href="http://quote.eastmoney.com/unify/r/116.01951" class="keytip" data-code="116,01951">锦欣生殖</a></span>，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.300015" class="em_stock_key_common" data-code="0,300015">爱尔眼科</span>、<span id="Info.116.02219"><a href="http://quote.eastmoney.com/unify/r/116.02219" class="keytip" data-code="116,02219">朝聚眼科</a></span>等；推荐业绩好的仿制药CRO 和中药CRO 的<span web="1" href="http://quote.eastmoney.com/unify/r/0.301096" class="em_stock_key_common" data-code="0,301096">百诚医药</span>和<span id="stock_1.688621"><a href="http://quote.eastmoney.com/unify/r/1.688621" class="keytip" data-code="1,688621">阳光诺和</a></span><span id="quote_1.688621"></span>；<span id="bk_90.BK1044"><a href="http://quote.eastmoney.com/unify/r/90.BK1044" class="keytip" data-code="90,BK1044">生物制品</a></span><span id="bkquote_90.BK1044"></span>，疫苗板块需要持续关注，我们推荐<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>、<span id="stock_1.688276"><a href="http://quote.eastmoney.com/unify/r/1.688276" class="keytip" data-code="1,688276">百克生物</a></span><span id="quote_1.688276"></span>、<span id="stock_1.688319"><a href="http://quote.eastmoney.com/unify/r/1.688319" class="keytip" data-code="1,688319">欧林生物</a></span><span id="quote_1.688319"></span>，建议关注<span id="stock_0.300142"><a href="http://quote.eastmoney.com/unify/r/0.300142" class="keytip" data-code="0,300142">沃森生物</a></span><span id="quote_0.300142"></span>、<span id="stock_1.688185"><a href="http://quote.eastmoney.com/unify/r/1.688185" class="keytip" data-code="1,688185">康希诺</a></span><span id="quote_1.688185"></span>、<span id="stock_1.603392"><a href="http://quote.eastmoney.com/unify/r/1.603392" class="keytip" data-code="1,603392">万泰生物</a></span><span id="quote_1.603392"></span>等；家用<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.002223" class="em_stock_key_common" data-code="0,002223">鱼跃医疗</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.301087" class="em_stock_key_common" data-code="0,301087">可孚医疗</span>。</p><p>(6)创新药板块，建议关注具备国际化能力的创新药标的，我们推荐<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>，建议关注<span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>、<span id="Info.116.06160"><a href="http://quote.eastmoney.com/unify/r/116.06160" class="keytip" data-code="116,06160">百济神州</a></span>、<span id="stock_0.300558"><a href="http://quote.eastmoney.com/unify/r/0.300558" class="keytip" data-code="0,300558">贝达药业</a></span><span id="quote_0.300558"></span>、<span id="Info.116.00013"><a href="http://quote.eastmoney.com/unify/r/116.00013" class="keytip" data-code="116,00013">和黄医药</a></span>、康方生物、<span id="Info.116.01177"><a href="http://quote.eastmoney.com/unify/r/116.01177" class="keytip" data-code="116,01177">中国生物制药</a></span>等。</p><p><strong>中银国际证券：疫情相关订单预期在2022年为CXO行业带来阶段性峰值</strong></p><p>疫情相关订单预期在2022 年为CXO 行业带来阶段性峰值，2023 年后CXO 行业将需要面临高基数下的增长压力，行业面临分化。企业需要通过技术和服务能力的优势获取更大份额的市场，而能力较差的公司则会面临增速下降的问题，CXO 行业投资将进入精挑细选时期。</p><p>目前全球CDMO 市场及中国CRO 安评领域市场集中度仍然较低，存在较大整合空间。同时，全球生物药研发热度带来相应的生物药CDMO 服务的较大需求，而生物药CDMO 产能仍然相对短缺，且产能掌握在少数龙头公司手中。中国生物药及细胞与基因研发热度带来相应CDMO 需求，中国CDMO企业积极在相应新兴领域进行布局。拥有技术与核心竞争力的龙头公司有望在化学小分子业务方面承接更多订单与更复杂的业务，并在生物大分子等新兴业务方面业绩有所增长。行业内竞争力较低的公司会面临整体增速降低的问题。投资预期将进入“精挑细选”时期，需要挑选拥有核心竞争力的CXO 企业进行投资。重点推荐：<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、<span id="stock_0.300759"><a href="http://quote.eastmoney.com/unify/r/0.300759" class="keytip" data-code="0,300759">康龙化成</a></span><span id="quote_0.300759"></span>、<span id="stock_1.603127"><a href="http://quote.eastmoney.com/unify/r/1.603127" class="keytip" data-code="1,603127">昭衍新药</a></span><span id="quote_1.603127"></span>。</p><p><strong><span id="stock_0.002736"><a href="http://quote.eastmoney.com/unify/r/0.002736" class="keytip" data-code="0,002736">国信证券</a></span><span id="quote_0.002736"></span>：新冠疫情仍为医药板块的最大主线 建议关注业绩弹性较大的板块</strong></p><p>一季度业绩表现亮眼，关注新冠检测相关板块。新冠检测相关标的22Q1业绩亮眼，国产厂商在新冠防治中的相对优势集中于检测领域，国内已广泛应用核酸检测，并于3月中旬开始使用抗原作为核酸检测的有效补充。国产厂商具备供应链、人力资源等优势，快速扩张产能，并以高性价比的优势在海外获得了大量订单，随着海外疫情管控放松和竞争格局恶化导致价格战等因素，将考验试剂厂商的订单获取能力。另外，国内多个城市如北京、上海、杭州、深圳等已经开始实施核酸检测常态化举措，有望为部分第三方检测企业带来业绩弹性。</p><p>板块估值处于低位，关注新冠带来的业绩弹性，以及低估值、业绩修复标的。新冠疫情仍为医药板块的最大主线，建议关注业绩弹性较大的板块。另外，建议关注回调幅度较大，且疫情后有业绩修复的标的。5月投资组合为A股：<span web="1" href="http://quote.eastmoney.com/unify/r/1.600276" class="em_stock_key_common" data-code="1,600276">恒瑞医药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、爱尔眼科、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300358" class="em_stock_key_common" data-code="0,300358">楚天科技</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000739" class="em_stock_key_common" data-code="0,000739">普洛药业</span>、<span id="stock_1.688617"><a href="http://quote.eastmoney.com/unify/r/1.688617" class="keytip" data-code="1,688617">惠泰医疗</a></span><span id="quote_1.688617"></span>；H股：<span id="Info.116.01066"><a href="http://quote.eastmoney.com/unify/r/116.01066" class="keytip" data-code="116,01066">威高股份</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.01951" class="em_stock_key_common" data-code="116,01951">锦欣生殖</span>、康诺亚、先瑞达医疗。</p><p><strong>万和证券：医药生物行业兼具强刚需、消费及科技属性</strong></p><p>医药生物行业兼具强刚需、消费及科技属性，伴随全国人口老龄化和科学技术的进步，行业整体发展前景十分乐观。基于目前医药行业整体较低的的市盈率，兼具成长性与确定性的优质赛道或迎接戴维斯双击。建议关注：1)旱涝保收的创新药服务商CXO；2)研发能力与消费属性双<span id="stock_106.JNJ"><a href="http://quote.eastmoney.com/unify/r/106.JNJ" class="keytip" data-code="106,JNJ">强生</a></span><span id="quote_106.JNJ"></span>物制品企业；3)受疫情影响压制的患者需求释放带来医院板块业绩反弹。</p><p><strong><span id="stock_1.600369"><a href="http://quote.eastmoney.com/unify/r/1.600369" class="keytip" data-code="1,600369">西南证券</a></span><span id="quote_1.600369"></span>：连锁药店集中度仍在持续提升 大连锁收购&自建门店空间大</strong></p><p>2021年公司直营连锁网络覆盖区域受到疫情影响较大，政府管控趋严，导致部分药物品种、门店客流、物流运输受限。随着疫情逐步好转，预期2022年大型连锁药店有望率先发力，引领行业复苏。</p><p>投资建议来看，我国连锁药店集中度仍在持续提升，大连锁收购&自建门店空间大；处方外流业务持续布局，预期有千亿规模可持续流向药店。两大因素均利好大型连锁药店。推荐<span web="1" href="http://quote.eastmoney.com/unify/r/1.603233" class="em_stock_key_common" data-code="1,603233">大参林</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002727" class="em_stock_key_common" data-code="0,002727">一心堂</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603883" class="em_stock_key_common" data-code="1,603883">老百姓</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603939" class="em_stock_key_common" data-code="1,603939">益丰药房</span>。</p><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/0.300059" class="em_stock_key_common" data-code="0,300059">东方财富</span>研究中心）</p>

<http://stock.eastmoney.com/news/1405,202205122377042913.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)